Financhill
Sell
46

TRUMY Quote, Financials, Valuation and Earnings

Last price:
$18.35
Seasonality move :
5.99%
Day range:
$18.22 - $18.72
52-week range:
$14.06 - $21.22
Dividend yield:
0.85%
P/E ratio:
34.92x
P/S ratio:
3.95x
P/B ratio:
2.96x
Volume:
182.1K
Avg. volume:
93.1K
1-year change:
8.9%
Market cap:
$27.1B
Revenue:
$6.8B
EPS (TTM):
$0.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TRUMY
Terumo
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$7.6B -- 2.75% -- $17.20
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TRUMY
Terumo
$18.35 -- $27.1B 34.92x $0.09 0.85% 3.95x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 22.97x
HLOSF
Healios KK
$3.17 -- $321.6M -- $0.00 0% 76.64x
PPTDF
PeptiDream
$13.53 -- $1.8B 16.80x $0.00 0% 5.80x
SOLTF
Nxera Pharma
$5.91 -- $531.3M -- $0.00 0% 2.96x
TAK
Takeda Pharmaceutical
$15.03 $17.20 $46.9B 68.88x $0.33 4.11% 1.61x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TRUMY
Terumo
11.33% -0.119 4.22% 1.67x
AMGXF
AnGes
-- 1.166 -- 1.28x
HLOSF
Healios KK
51.17% -0.602 6.95% 1.11x
PPTDF
PeptiDream
25.74% 0.569 5.48% 4.62x
SOLTF
Nxera Pharma
48.1% 1.893 78.18% 2.83x
TAK
Takeda Pharmaceutical
39.43% -0.370 64.47% 0.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TRUMY
Terumo
$951.4M $300.1M 7.51% 8.61% 17.57% $215.3M
AMGXF
AnGes
$368.5K -$8.2M -33.92% -33.92% -741.83% --
HLOSF
Healios KK
$59K -$4.9M -85.83% -196.15% -1239.47% -$5.1M
PPTDF
PeptiDream
$9.6M -$9M 23.58% 34.1% -29.18% -$69.4M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M
TAK
Takeda Pharmaceutical
$4.4B -$491.4M 0.89% 1.49% -5.41% $854.8M

Terumo vs. Competitors

  • Which has Higher Returns TRUMY or AMGXF?

    AnGes has a net margin of 13.44% compared to Terumo's net margin of -737.34%. Terumo's return on equity of 8.61% beat AnGes's return on equity of -33.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMY
    Terumo
    55.06% $0.16 $10.3B
    AMGXF
    AnGes
    33.2% -$0.03 $21.5M
  • What do Analysts Say About TRUMY or AMGXF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than AnGes, analysts believe Terumo is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMY
    Terumo
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is TRUMY or AMGXF More Risky?

    Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TRUMY or AMGXF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.85%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMY or AMGXF?

    Terumo quarterly revenues are $1.7B, which are larger than AnGes quarterly revenues of $1.1M. Terumo's net income of $232.2M is higher than AnGes's net income of -$8.2M. Notably, Terumo's price-to-earnings ratio is 34.92x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.95x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMY
    Terumo
    3.95x 34.92x $1.7B $232.2M
    AMGXF
    AnGes
    22.97x -- $1.1M -$8.2M
  • Which has Higher Returns TRUMY or HLOSF?

    Healios KK has a net margin of 13.44% compared to Terumo's net margin of -6742.11%. Terumo's return on equity of 8.61% beat Healios KK's return on equity of -196.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMY
    Terumo
    55.06% $0.16 $10.3B
    HLOSF
    Healios KK
    23.68% -$0.18 $26.9M
  • What do Analysts Say About TRUMY or HLOSF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Healios KK, analysts believe Terumo is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMY
    Terumo
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is TRUMY or HLOSF More Risky?

    Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock TRUMY or HLOSF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.85%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMY or HLOSF?

    Terumo quarterly revenues are $1.7B, which are larger than Healios KK quarterly revenues of $249.2K. Terumo's net income of $232.2M is higher than Healios KK's net income of -$16.8M. Notably, Terumo's price-to-earnings ratio is 34.92x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.95x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMY
    Terumo
    3.95x 34.92x $1.7B $232.2M
    HLOSF
    Healios KK
    76.64x -- $249.2K -$16.8M
  • Which has Higher Returns TRUMY or PPTDF?

    PeptiDream has a net margin of 13.44% compared to Terumo's net margin of -24.41%. Terumo's return on equity of 8.61% beat PeptiDream's return on equity of 34.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMY
    Terumo
    55.06% $0.16 $10.3B
    PPTDF
    PeptiDream
    34.69% -$0.05 $493M
  • What do Analysts Say About TRUMY or PPTDF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than PeptiDream, analysts believe Terumo is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMY
    Terumo
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is TRUMY or PPTDF More Risky?

    Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

  • Which is a Better Dividend Stock TRUMY or PPTDF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.85%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMY or PPTDF?

    Terumo quarterly revenues are $1.7B, which are larger than PeptiDream quarterly revenues of $27.8M. Terumo's net income of $232.2M is higher than PeptiDream's net income of -$6.8M. Notably, Terumo's price-to-earnings ratio is 34.92x while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.95x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMY
    Terumo
    3.95x 34.92x $1.7B $232.2M
    PPTDF
    PeptiDream
    5.80x 16.80x $27.8M -$6.8M
  • Which has Higher Returns TRUMY or SOLTF?

    Nxera Pharma has a net margin of 13.44% compared to Terumo's net margin of -11.44%. Terumo's return on equity of 8.61% beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMY
    Terumo
    55.06% $0.16 $10.3B
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About TRUMY or SOLTF?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Terumo has higher upside potential than Nxera Pharma, analysts believe Terumo is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMY
    Terumo
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is TRUMY or SOLTF More Risky?

    Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

  • Which is a Better Dividend Stock TRUMY or SOLTF?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.85%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terumo pays 30.45% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TRUMY or SOLTF?

    Terumo quarterly revenues are $1.7B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Terumo's net income of $232.2M is higher than Nxera Pharma's net income of -$5M. Notably, Terumo's price-to-earnings ratio is 34.92x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.95x versus 2.96x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMY
    Terumo
    3.95x 34.92x $1.7B $232.2M
    SOLTF
    Nxera Pharma
    2.96x -- $43.6M -$5M
  • Which has Higher Returns TRUMY or TAK?

    Takeda Pharmaceutical has a net margin of 13.44% compared to Terumo's net margin of -9.79%. Terumo's return on equity of 8.61% beat Takeda Pharmaceutical's return on equity of 1.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    TRUMY
    Terumo
    55.06% $0.16 $10.3B
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
  • What do Analysts Say About TRUMY or TAK?

    Terumo has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.20 which suggests that it could grow by 13.18%. Given that Takeda Pharmaceutical has higher upside potential than Terumo, analysts believe Takeda Pharmaceutical is more attractive than Terumo.

    Company Buy Ratings Hold Ratings Sell Ratings
    TRUMY
    Terumo
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is TRUMY or TAK More Risky?

    Terumo has a beta of 0.803, which suggesting that the stock is 19.744% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

  • Which is a Better Dividend Stock TRUMY or TAK?

    Terumo has a quarterly dividend of $0.09 per share corresponding to a yield of 0.85%. Takeda Pharmaceutical offers a yield of 4.11% to investors and pays a quarterly dividend of $0.33 per share. Terumo pays 30.45% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Terumo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios TRUMY or TAK?

    Terumo quarterly revenues are $1.7B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Terumo's net income of $232.2M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Terumo's price-to-earnings ratio is 34.92x while Takeda Pharmaceutical's PE ratio is 68.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terumo is 3.95x versus 1.61x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TRUMY
    Terumo
    3.95x 34.92x $1.7B $232.2M
    TAK
    Takeda Pharmaceutical
    1.61x 68.88x $6.9B -$676.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Best AI Index Fund to Buy
Best AI Index Fund to Buy

Over the last two years, companies with a focus on…

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for Jun 2

Regeneron Pharmaceuticals [REGN] is down 0.26% over the past day.

Buy
55
RGC alert for Jun 2

Regencell Bioscience Holdings [RGC] is up 4.79% over the past day.

Sell
42
AMBA alert for Jun 2

Ambarella [AMBA] is up 0.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock